An update of novel therapeutic approaches for multiple myeloma

Current Treatment Options in Oncology

Volumn 5, Issue 3, 2004, Pages 227-238

  Richardson, Paul ^a   Hideshima, Teru ^b   Anderson, Kenneth C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTHRACYCLINE; ARSENIC TRIOXIDE; BORTEZOMIB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LENALIDOMIDE; LONAFARNIB; MELPHALAN; PACLITAXEL; PAMIDRONIC ACID; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; THALIDOMIDE; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; VINCRISTINE; VORINOSTAT; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ANEMIA; BONE DISEASE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; MICROENVIRONMENT; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; REGULATORY MECHANISM; REVIEW; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; DRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA;

EID: 4444237811     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0014-6     Document Type: Review

References (100)

1. Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2: 175-187.
2. Anderson KC: Targeted therapy for multiple myeloma. Semin Hematol 2001, 38: 286-297.
3. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992, 10: 334-342.
4. Attal M, Harousseau JL: Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001, 38: 226-230.
5. Desikan R, Barlogie B, Sawyer J, et al.: Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000, 95: 4008-4010.
6. Attal M, Harousseau JL, Facon T, et al.: Single versus double autologous stem cell transplant for multiple myeloma. N Engl J Med 2003, 349: 2495-2502.
7. Massaia M, Borrione P, Battaglio S, et al.: Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999, 94: 673-683.
8. Gahrton G, Tura S, Ljungman P, et al.: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991, 325: 1267-1273.
9. Gahrton G, Svensson H, Cavo M, et al.: Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow centers. Br J Haematol 2001, 113: 209-216.
10. Alyea E, Weller E, Schlossman R, et al.: T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001, 98: 934-939.
11. Badros A, Barlogie B, Morris C, et al.: High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97: 2574-2579.
12. Kroger N, Schwerdtfeger R, Kiehl M, et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100: 755-760.
13. Berenson JR, Hillner BE, Kyle RA, et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20: 3719-3736.
14. Grogan T, Spier CM, Salmon SE, et al.: P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81: 490-495.
15. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341: 1565-1571.
16. Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase II study of 169 patients. Blood 2001, 98: 492-494.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91: 4082-4085.
18. Teoh G, Anderson KC: Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11: 27-42.
19. Lichtenstein A, Tu Y, Fady C, et al.: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995, 162: 248-255.
20. Chauhan D, Kharbanda S, Ogata A, et al.: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89: 227-234.
21. Ogata A, Chauhan D, Teoh G, et al.: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997, 159: 2212-2221.
22. Tu Y, Gardner A, Lichtenstein A: The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000, 60: 6763-6770.
23. Hideshima T, Nakamura N, Chauhan D, Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20: 5991-6000.
24. Freund GG, Kulas DT, Mooney RA: Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 1993, 151: 1811-1820.
25. Ogawa M, Nishiura T, Oritani K, et al.: Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000, 60: 4262-4269.
26. Mitsiades CS, Mitsiades N, Poulaki V, et al.: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21: 5673-5683.
27. Brenne AT, Baade Ro T, Waage A, et al.: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99: 3756-3762.
28. Podar K, Tai YT, Davies FE, et al.: Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98: 428-435.
29. Podar K, Tai YT, Lin BK, et al.: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα activation. J Biol Chem 2002, 277: 7875-7881.
30. Hideshima T, Chauhan D, Hayashi T, et al.: The biologic sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther 2002, 1: 539-544.
31. Uchiyama H, Barut BA, Mohrbacher AF, et al.: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82: 3712-3720.
32. Chauhan D, Uchiyama H, Akbarali Y, et al.: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996, 87: 1104-1112.
33. Dankbar B, Padro T, Leo R, et al.: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95: 2630-2636.
34. Gupta D, Treon SP, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15: 1950-1961.
35. Hideshima T, Chauhan D, Schlossman R, et al.: The role of tumor necrosis factor α in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene 2001, 20: 4519-4527.
36. Qiang YW, Kopantzev E, Rudikoff S: Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002, 99: 4138-4146.
37. Covelli A: Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999, 10: 53-59.
38. Schwarzenbach H: Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002, 19: 87-104.
39. Damiano JS, Cress AE, Hazlehurst LA, et al.: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93: 1658-1667.
40. Hazlehurst LA, Damiano JS, Buyuksal I, et al.: Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR . Oncogene 2000, 19: 4319-4327.
41. Mitsiades CS, Treon SP, Mitsiades N, et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001, 98: 795-804.
42. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99: 4525-4530.
43. Chauhan D, Pandey P, Hideshima T, et al.: SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000, 275: 27845-27850.
44. Hayashi T, Hideshima T, Akiyama M, et al.: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002, 1: 851-860.
45. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002, 99: 14374-14379.
46. Chauhan D, Hideshima T, Pandey P, et al.: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene 1999, 18: 6733-6740.
47. Chauhan D, Hideshima T, Rosen S, et al.: Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001, 276: 24453-24456.
48. Dalton WS, Jove R: Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999, 26: 23-27.
49. Puthier D, Bataille R, Amiot M: IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999, 29: 3945-3950.
50. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99: 4079-4086.
51. Hideshima T, Chauhan D, Richardson P, et al.: NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277: 16639-16647.
52. Richardson P, Hideshima T, Anderson KC: Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002, 53: 629-657.
53. Ribatti D, Vacca A, De Falco G, et al.: Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Res 2001, 21: 4333-4339.
54. Vacca A, Ribatti D, Presta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93: 3064-3073.
55. Rajkumar SV, Hayman S, Fertz M, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 21: 4319-4323.
56. Weber D, Rankin K, Gavino M, et al.: Thalidomide alone or with dexamethasone for previously untreated myeloma. J Clin Oncol 2003, 21: 16-19.
57. Hideshima T, Chauhan D, Shima Y, et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96: 2943-2950.
58. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98: 210-216.
59. Lentzsch S, Rogers MS, LeBlanc R, et al.: S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B- cell neoplasias in mice. Cancer Res 2002, 62: 2300-2305.
60. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.. Blood 2002, 100: 3063-3067.
61. King RW, Deshaies RJ, Peters JM, Kirschner MW: How proteolysis drives the cell cycle. Science 1996, 274: 1652-1959.
62. Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8: 739-758.
63. Adams J, Palombella VJ, Sausville EA, et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59: 2615-2622.
64. Orkowski RZ, Eswara JR, Lafond-Walker A, et al.: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58: 4342-4348.
65. Tan C, Waldmann TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002, 62: 1083-1086.
66. Teicher BA, Ara G, Herbst R, et al.: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5: 2638-2645.
67. Harbison MT, Bruns CJ: Proteasome inhibitor PS-341 is effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-κB and subsequent inhibition of vascular endothelial growth factor production. Proc Am Assoc Cancer Res 2000, 41: 71.
68. Hideshima T, Richardson P, Chauhan D, et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res 2001, 61: 3071-3076.
69. Hideshima T, Mitsiades C, Akiyama M, et al.: Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 2003, 101: 1530-1534.
70. Mitsiades N, Mitsiades CS, Richardson PG, et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101: 2377-2380.
71. LeBlanc R, Catley LP, Hideshima T, et al.: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002, 62: 4996-5000.
72. Orlowski R, Stinchcombe TE, Mitchell BS, et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 22: 4420-4427.
73. Richardson PG, Barlogie B, Berenson J, et al.: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348: 2609-2617.
74. Barlogie B, Shaughnessy J, Tricot G, et al.: Treatment of myeloma. Blood 2004, 103: 20-32.
75. Shao W, Fanelli M, Ferrara FF, et al.: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998, 90: 124-133.
76. Rousselot P, Labaume S, Marolleau JP, et al.: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999, 59: 1041-1048.
77. Park WH, Seol JG, Kim ES, et al.: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000, 60: 3065-3071.
78. Deaglio S, Canella D, Baj G, et al.: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells. Leuk Res 2001, 25: 227-325.
79. Hussein MA: Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol 2001, 18: 239-242.
80. Grad JM, Bahlis NJ, Reis I, et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98: 805-813.
81. Lin B, Podar K, Gupta D, et al.: The vascular endothelial growth factor receptor kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002, 62: 5019-5026.
82. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-(TRAIL) induced apoptosis in human multiple myeloma cells. Blood 2002, 99: 2162-2171.
83. D'Amato RJ, Lin CM, Flynn E, et al.: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994, 91: 3964-3968.
84. Klauber N, Parangi S, Flynn E, et al.: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997, 57: 81-86.
85. Chauhan D, Catley L, Hideshima T, et al.: 2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma. Blood 2002, 100: 2187-2194.
86. Kato K, Cox AD, Hisaka MM, et al.: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 1992, 89: 6403-6407.
87. Karp JE, Kaufmann SH, Adjei AA, et al.: Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 2001, 13:470-476.
88. Mitsiades N, Mitsiades CS, Poulaki V, et al.: The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell lines and patient tumor cells. Blood 2001, 98: 376a.
89. Mitsiades CS, Mitsiades N, Richardson P, et al.: The HSP90 molecular chaperone as a novel therapeutic target in hematologic malignancies. Blood 2001, 98: 377a.
90. Garrett IR, Durie BG, Nedwin GE, et al.: Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987, 317: 526-532.
91. Barille S, Bataille R, Rapp MJ et al.: Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999, 163: 5723-5728.
92. Lacy MQ, Donovan KA, Heimbach JK, et al.: Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999, 93: 300-305.
93. Han JH, Choi SJ, Kurihara N, et al.: Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97: 3349-3353.
94. Choi SJ, Cruz JC, Craig F, et al.: Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96: 671-675.
95. Seidel C, Sundan A, Hjorth M, et al.: Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000, 95: 388-392.
96. Giuliani N, Bataille R, Mancini C, et al.: Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98: 3527-3533.
97. Pearse RN, Sordillo EM, Yaccoby S, et al.: Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001, 98: 11581-11586.
98. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334: 488-493.
99. Derenne S, Amiot M, Barille S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999, 14: 2048-2056.
100. Oyajobi BO, Anderson DM, Traianedes K, et al.: Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001, 61: 2572-2578.